Alignment of SID 93 w/ Wallach AA

DR WPI; 1999-070258/06.
DR N-PSDB; AAX02558.
XX
PT New B1 protein regulates cell death and cell survival pathways -
PT derivatives, DNA and antibodies, also regulate intracellular inflammation
PT ; for treating AIDS, cancer.
XX
PS Claim 4; Fig 3A; 90pp; English.
XX
CC This invention describes the isolation of a novel human B1 protein which
CC can interact with, intracellular mediators or modulators of inflammation,
CC cell death and/or cell survival pathways, directly or indirectly. Cells
CC can be modulated or mediated in inflammation, cell death or cell survival
CC pathways or another intracellular signalling activity using B1.
CC Conditions such as AIDS and cancer can be treated using B1. Antibodies,
CC oligonucleotides and ribozymes can also be used to regulate the above
CC pathways
XX
SQ Sequence 540 AA;

Query Match 97.8%; Score 227; DB 2; Length 540;
Best Local Similarity 100.0%; Pred. No. 1e-221;
Matches 227; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          6 LQSVSSAIHLCDKKKMELSLNIPVNHGPQEESCGSSQLHENSGSPETSRSLPAPQDNDFL 65
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        314 LQSVSSAIHLCDKKKMELSLNIPVNHGPQEESCGSSQLHENSGSPETSRSLPAPQDNDFL 373

Qy         66 SRKAQDCYFMKLHHCPGNHSWDSTISGSQRAAFCDHKTTPCSSAIINPLSTAGNSERLQP 125
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        374 SRKAQDCYFMKLHHCPGNHSWDSTISGSQRAAFCDHKTTPCSSAIINPLSTAGNSERLQP 433

Qy        126 GIAQQWIQSKREDIVNQMTEACLNQSLDALLSRDLIMKEDYELVSTKPTRTSKVRQLLDT 185
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        434 GIAQQWIQSKREDIVNQMTEACLNQSLDALLSRDLIMKEDYELVSTKPTRTSKVRQLLDT 493

Qy        186 TDIQGEEFAKVIVQKLKDNKQMGLQPYPEILVVSRSPSLNLLQNKSM 232
              |||||||||||||||||||||||||||||||||||||||||||||||
Db        494 TDIQGEEFAKVIVQKLKDNKQMGLQPYPEILVVSRSPSLNLLQNKSM 540
```

RESULT 4
AAW92795
ID AAW92795 standard; protein; 540 AA.
XX
AC AAW92795;
XX
DT 07-MAY-1999 (first entry)
XX
DE Human B1 protein.
XX
KW B1 protein; intracellular mediator; modulator; inflammation; cell death;
KW cell survival pathway; intracellular signalling; AIDS; cancer; human.
XX
OS Homo sapiens.
XX
PN WO9855507-A2.
XX
PD 10-DEC-1998. (b)
XX
PF 01-JUN-1998; 98WO-IL000255.
XX
PR 05-JUN-1997; 97IL-00121011.
PR 30-JUN-1997; 97IL-00121199.
PR 11-SEP-1997; 97IL-00121746.
XX
PA (YEDA) YEDA RES & DEV CO LTD.
XX
PI Wallach D, Boldin M, Malinin N;
XX

Alignment of SID2 w/ Wallach AA

AAW92795
ID AAW92795 standard; protein; 540 AA.
XX
AC AAW92795;
XX
DT 07-MAY-1999 (first entry)
XX
DE Human B1 protein.
XX
KW B1 protein; intracellular mediator; modulator; inflammation; cell death;
KW cell survival pathway; intracellular signalling; AIDS; cancer; human.
XX
OS Homo sapiens.
XX
PN WO9855507-A2.
XX
PD 10-DEC-1998.
XX
PF 01-JUN-1998; 98WO-IL000255.
XX
PR 05-JUN-1997; 97IL-00121011.
PR 30-JUN-1997; 97IL-00121199.
PR 11-SEP-1997; 97IL-00121746.
XX
PA (YEDA) YEDA RES & DEV CO LTD.
XX
PI Wallach D, Boldin M, Malinin N;
XX
DR WPI; 1999-070258/06.
DR N-PSDB; AAX02558.
XX
PT New B1 protein regulates cell death and cell survival pathways -
PT derivatives, DNA and antibodies, also regulate intracellular inflammation
PT ; for treating AIDS, cancer.
XX
PS Claim 4; Fig 3A; 90pp; English.
XX
CC This invention describes the isolation of a novel human B1 protein which
CC can interact with, intracellular mediators or modulators of inflammation,
CC cell death and/or cell survival pathways, directly or indirectly. Cells
CC can be modulated or mediated in inflammation, cell death or cell survival
CC pathways or another intracellular signalling activity using B1.
CC Conditions such as AIDS and cancer can be treated using B1. Antibodies,
CC oligonucleotides and ribozymes can also be used to regulate the above
CC pathways

ce 540 AA;

e:

Pred. No.:	2.86e-237	Length:	540
Score:	227.00	Matches:	227
Percent Similarity:	100.00%	Conservative:	0
Best Local Similarity:	100.00%	Mismatches:	0
Query Match:	42.75%	Indels:	0
DB:	2	Gaps:	0

US-09-771-161A-2 (1-1669) x AAW92795 (1-540)

```
Qy        335 TTACAGAGTGTTTCAAGTGCCATTCACCTATGTGACAAGAAGAAAATGGAATTATCTCTG 394
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        314 LeuGlnSerValSerSerAlaIleHisLeuCysAspLysLysLysMetGluLeuSerLeu 333

Qy        395 AACATACCTGTAAATCATGGTCCACAAGAGGAATCATGTGGATCCTCTCAGCTCCATGAA 454
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        334 AsnIleProValAsnHisGlyProGlnGluGluSerCysGlySerSerGlnLeuHisGlu 353

Qy        455 AATAGTGGTTCTCCTGAAACTTCAAGGTCCCTGCCAGCTCCTCAAGACAATGATTTTTTA 514
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        354 AsnSerGlySerProGluThrSerArgSerLeuProAlaProGlnAspAsnAspPheLeu 373

Qy        515 TCTAGAAAAGCTCAAGACTGTTATTTTATGAAGCTGCATCACTGTCCTGGAAATCACAGT 574
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        374 SerArgLysAlaGlnAspCysTyrPheMetLysLeuHisHisCysProGlyAsnHisSer 393

Qy        575 TGGGATAGCACCATTTCTGGATCTCAAAGGGCTGCATTCTGTGATCACAAGACCACTCCA 634
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        394 TrpAspSerThrIleSerGlySerGlnArgAlaAlaPheCysAspHisLysThrThrPro 413

Qy        635 TGCTCTTCAGCAATAATAAATCCACTCTCAACTGCAGGAAACTCAGAACGTCTGCAGCCT 694
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        414 CysSerSerAlaIleIleAsnProLeuSerThrAlaGlyAsnSerGluArgLeuGlnPro 433

Qy        695 GGTATAGCCCAGCAGTGGATCCAGAGCAAAAGGGAAGACATTGTGAACCAAATGACAGAA 754
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        434 GlyIleAlaGlnGlnTrpIleGlnSerLysArgGluAspIleValAsnGlnMetThrGlu 453

Qy        755 GCCTGCCTTAACCAGTCGCTAGATGCCCTTCTGTCCAGGGACTTGATCATGAAAGAGGAC 814
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        454 AlaCysLeuAsnGlnSerLeuAspAlaLeuLeuSerArgAspLeuIleMetLysGluAsp 473

Qy        815 TATGAACTTGTTAGTACCAAGCCTACAAGGACCTCAAAAGTCAGACAATTACTAGACACT 874
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        474 TyrGluLeuValSerThrLysProThrArgThrSerLysValArgGlnLeuLeuAspThr 493

Qy        875 ACTGACATCCAAGGAGAAGAATTTGCCAAAGTTATAGTACAAAAATTGAAAGATAACAAA 934
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        494 ThrAspIleGlnGlyGluGluPheAlaLysValIleValGlnLysLeuLysAspAsnLys 513

Qy        935 CAAATGGGTCTTCAGCCTTACCCGGAAATACTTGTGGTTTCTAGATCACCATCTTTAAAT 994
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        514 GlnMetGlyLeuGlnProTyrProGluIleLeuValValSerArgSerProSerLeuAsn 533

Qy        995 TTACTTCAAAATAAAAGCATG 1015
              |||||||||||||||||||||
Db        534 LeuLeuGlnAsnLysSerMet 540
```

RESULT 5
AAY68774
ID AAY68774 standard; protein; 540 AA.
XX
AC AAY68774;
XX
DT 16-MAY-2000 (first entry)
XX
DE Amino acid sequence of a human phosphorylation effector PHSP-6.
XX
KW Human; phosphorylation effector; PHSP; proliferative disorder;
KW immune disorder; neuronal disorder.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers

Alignment of SID2 w/ Wallach et al NT

cirrhosis, hepatitis and cancer, developmental disorders e.g. mental retardation, neurological disorders including Alzheimer's disease and Parkinson's disease, autoimmune and inflammatory disorders such as Crohn's disease and diabetes mellitus and finally, viral, bacterial, fungal, parasitic, protozoan or helminthic infections. Furthermore, the polynucleotides encoding KPP may be useful for creating transgenic animals to model human disease, as well as during gene therapy procedures. The current sequence is that of the human KPP cDNA of the invention.

Sequence 1959 BP; 597 A; 430 C; 420 G; 512 T; 0 U; 0 Other;

Query Match 47.0%; Score 785; DB 9; Length 1959;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 785; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

423 AGGAATCATGTGGATCCTCTCAGCTCCATGAAAATAGTGGTTCTCCTGAAACTTCAAGGT 482

RESULT 8
AAX02558
ID AAX02558 standard; cDNA; 2098 BP.
XX
AC AAX02558;
XX
DT 07-MAY-1999 (first entry)
XX
DE Human B1 cDNA.
XX
KW B1 protein; intracellular mediator; modulator; inflammation;
KW cell survival pathway; intracellular signalling; AIDS; cancer;
XX
OS Homo sapiens.
XX
PN WO9855507-A2.
XX

PD 10-DEC-1998.
XX
PF 01-JUN-1998; 98WO-IL000255.
XX
PR 05-JUN-1997; 97IL-00121011.
PR 30-JUN-1997; 97IL-00121199.
PR 11-SEP-1997; 97IL-00121746.
XX
PA (YEDA) YEDA RES & DEV CO LTD.
XX
PI Wallach D, Boldin M, Malinin N;
XX
DR WPI; 1999-070258/06.
DR P-PSDB; AAW92795.
XX
PT New B1 protein regulates cell death and cell survival pathways -
PT derivatives, DNA and antibodies, also regulate intracellular inflammation
PT ; for treating AIDS, cancer.
XX
PS Claim 4; Fig 3B; 90pp; English.
XX
CC This invention describes the isolation of a novel human B1 protein which
CC can interact with, intracellular mediators or modulators of inflammation,
CC cell death and/or cell survival pathways, directly or indirectly. Cells
CC can be modulated or mediated in inflammation, cell death or cell survival
CC pathways or another intracellular signalling activity using B1.
CC Conditions such as AIDS and cancer can be treated using B1. Antibodies,
CC oligonucleotides and ribozymes can also be used to regulate the above
CC pathways
XX
SQ Sequence 2098 BP; 649 A; 452 C; 449 G; 539 T; 0 U; 9 Other;

Query Match 46.9%; Score 783; DB 2; Length 2098;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 783; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       333 AGTTACAGAGTGTTTCAAGTGCCATTCACCTATGTGACAAGAAGAAAATGGAATTATCTC 392
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1197 AGTTACAGAGTGTTTCAAGTGCCATTCACCTATGTGACAAGAAGAAAATGGAATTATCTC 1256

Qy       393 TGAACATACCTGTAAATCATGGTCCACAAGAGGAATCATGTGGATCCTCTCAGCTCCATG 452
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1257 TGAACATACCTGTAAATCATGGTCCACAAGAGGAATCATGTGGATCCTCTCAGCTCCATG 1316

Qy       453 AAAATAGTGGTTCTCCTGAAACTTCAAGGTCCCTGCCAGCTCCTCAAGACAATGATTTTT 512
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1317 AAAATAGTGGTTCTCCTGAAACTTCAAGGTCCCTGCCAGCTCCTCAAGACAATGATTTTT 1376

Qy       513 TATCTAGAAAAGCTCAAGACTGTTATTTTATGAAGCTGCATCACTGTCCTGGAAATCACA 572
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1377 TATCTAGAAAAGCTCAAGACTGTTATTTTATGAAGCTGCATCACTGTCCTGGAAATCACA 1436

Qy       573 GTTGGGATAGCACCATTTCTGGATCTCAAAGGGCTGCATTCTGTGATCACAAGACCACTC 632
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1437 GTTGGGATAGCACCATTTCTGGATCTCAAAGGGCTGCATTCTGTGATCACAAGACCACTC 1496

Qy       633 CATGCTCTTCAGCAATAATAAATCCACTCTCAACTGCAGGAAACTCAGAACGTCTGCAGC 692
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1497 CATGCTCTTCAGCAATAATAAATCCACTCTCAACTGCAGGAAACTCAGAACGTCTGCAGC 1556

Qy       693 CTGGTATAGCCCAGCAGTGGATCCAGAGCAAAAGGGAAGACATTGTGAACCAAATGACAG 752
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1557 CTGGTATAGCCCAGCAGTGGATCCAGAGCAAAAGGGAAGACATTGTGAACCAAATGACAG 1616

Qy       753 AAGCCTGCCTTAACCAGTCGCTAGATGCCCTTCTGTCCAGGGACTTGATCATGAAAGAGG 812
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1617 AAGCCTGCCTTAACCAGTCGCTAGATGCCCTTCTGTCCAGGGACTTGATCATGAAAGAGG 1676

Qy       813 ACTATGAACTTGTTAGTACCAAGCCTACAAGGACCTCAAAAGTCAGACAATTACTAGACA 872
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1677 ACTATGAACTTGTTAGTACCAAGCCTACAAGGACCTCAAAAGTCAGACAATTACTAGACA 1736

         873 CTACTGACATCCAAGGAGAAGAATTTGCCAAAGTTATAGTACAAAAATTGAAAGATAACA 932
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1737 CTACTGACATCCAAGGAGAAGAATTTGCCAAAGTTATAGTACAAAAATTGAAAGATAACA 1796

Qy       933 AACAAATGGGTCTTCAGCCTTACCCGGAAATACTTGTGGTTTCTAGATCACCATCTTTAA 992
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1797 AACAAATGGGTCTTCAGCCTTACCCGGAAATACTTGTGGTTTCTAGATCACCATCTTTAA 1856

Qy       993 ATTTACTTCAAAATAAAAGCATGTAAGTGACTGTTTTTCAAGAAGAAATGTGTTTCATAA 1052
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1857 ATTTACTTCAAAATAAAAGCATGTAAGTGACTGTTTTTCAAGAAGAAATGTGTTTCATAA 1916

Qy      1053 AAGGATATTTATATCTCTGTTGCTTTGACTTTTTTTATATAAAATCCGTGAGTATTAAAG 1112
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1917 AAGGATATTTATATCTCTGTTGCTTTGACTTTTTTTATATAAAATCCGTGAGTATTAAAG 1976

Qy      1113 CTT 1115
            |||
Db      1977 CTT 1979
```

Alignment of AF027706 w/ Wallach NT

RESULT 2
AAX02558
ID AAX02558 standard; cDNA; 2098 BP.
XX
AC AAX02558;
XX
DT 07-MAY-1999 (first entry)
XX
DE Human B1 cDNA.
XX
KW B1 protein; intracellular mediator; modulator; inflammation; cell death;
KW cell survival pathway; intracellular signalling; AIDS; cancer; human; ss.
XX
OS Homo sapiens.
XX
PN WO9855507-A2.
XX
PD 10-DEC-1998.
XX
PF 01-JUN-1998; 98WO-IL000255.
XX
PR 05-JUN-1997; 97IL-00121011.
PR 30-JUN-1997; 97IL-00121199.
PR 11-SEP-1997; 97IL-00121746.
XX
PA (YEDA) YEDA RES & DEV CO LTD.
XX
PI Wallach D, Boldin M, Malinin N;
XX
DR WPI; 1999-070258/06.
DR P-PSDB; AAW92795.
XX
PT New B1 protein regulates cell death and cell survival pathways -
PT derivatives, DNA and antibodies, also regulate intracellular inflammation
PT ; for treating AIDS, cancer.
XX
PS Claim 4; Fig 3B; 90pp; English.
XX
CC This invention describes the isolation of a novel human B1 protein which
CC can interact with, intracellular mediators or modulators of inflammation,
CC cell death and/or cell survival pathways, directly or indirectly. Cells
CC can be modulated or mediated in inflammation, cell death or cell survival
CC pathways or another intracellular signalling activity using B1.
CC Conditions such as AIDS and cancer can be treated using B1. Antibodies,
CC oligonucleotides and ribozymes can also be used to regulate the above
CC pathways
XX
SQ Sequence 2098 BP; 649 A; 452 C; 449 G; 539 T; 0 U; 9 Other;

Query Match 80.7%; Score 2017.8; DB 3; Length 2098;
Best Local Similarity 99.3%; Pred. No. 1.1e-06;
Matches 2016; Conservative 9; Mismatches 6; Indels 0; Gaps 0;

AF027706

```
Qy    1 GGCACCAGTCTCTAGAAAAGAAGTCAGCTCTGGTTCGGAGAAGCAGCGGCTGGCGTGGGC 60
Db    36 GGCACCAGTCTCTAGAAAAGAAGTCAGCTCTGGTTCGGAGAAGCAGCGGCTGGCGTGGGC 95
Qy   61 CATCCGGGGAATGGGCGCCCTCGTGACCTAGTGTTGCGGGGCAAAAAGGGTCTTGCCGGC 120
Db   96 CATCCGGGGAATGGGCGCCCTCGTGACCTAGTGTTGCGGGGCAAAAAGGGTCTTGCCGGC 155
Qy  121 CTCGCTCGTGCAGGGGCGTATCTGGGCGCCTGAGCGCGCAGTGGGAGCCTTGGGAGCCGC 180
Db  156 CTCGCTCGTGCAGGGGCGTATCTGGGCGCCTGAGCGCGGCGTGGGAGCCTTGGGAGCCGC 215
Qy  181 CGCAGCAGGGGGCACACCCGGAACCGGCCTGAGCGCCCGGGACCATGAACGGGGAGGCCA 240
Db  216 CGCAGCAGGGGGCACACCCGGAACCGGCCTGAGCGCCCGGGACCATGAACGGGGAGGCCA 275
Qy  241 TCTGCAGCGCCCTGCCCACCATTCCCTACCACAAACTCGCCGACCTGCGCTACCTGAGCC 300
Db  276 TCTGCAGCGCCCTGCCCACCATTCCCTACCACAAACTCGCCGACCTGCGCTACCTGAGCC 335
Qy  301 GCGGCGCCTCTGGCACTGTGTCGTCCGCCCGCCACGCAGACTGGCGCGTCCAGGTGGCCG 360
Db  336 GCGGCGCCTCTGGCACTGTGTCGTCCGCCCGCCACGCAGACTGGCGCGTCCAGGTGGCCG 395
Qy  361 TGAAGCACCTGCACATCCACACTCCGCTGCTCGACAGTGAAAGAAAGGATGTCTTAAGAG 420
Db  396 TGAAGCACCTGCACATCCACACTCCGCTGCTCGACAGTGAAAGAAAGGATGTTTTAAGAG 455
Qy  421 AAGCTGAAATTTTACACAAAGCTAGATTTAGTTACATTCTTCCAATTTTGGGAATTTGCA 480
Db  456 AAGCTGAAATTTTACACAAAGCTAGATTTAGTTACATTTTTCCAATTTTGGGAATTTGCA 515
Qy  481 ATGAGCCTGAATTTTTGGGAATAGTTACTGAATACATGCCAAATGGATCATTAAATGAAC 540
Db  516 ATGAGCCTGAATTTTTGGGAATAGTTACTGAATACATGCCAAATGGATCATTAAATGAAC 575
Qy  541 TCCTACATAGGAAAACTGAATATCCTGATGTTGCTTGGCCATTGAGATTTCGCATCCTGC 600
Db  576 TCCTACATAGGAAAACTGAATATCCTGATGTTGCTTGGCCATTGAGATTTCGCATCCTGC 635
Qy  601 ATGAAATTGCCCTTGGTGTAAATTACCTGCACAATATGACTCCTCCTTTACTTCATCATG 660
Db  636 ATGAAATTGCCCTTGGTGTAAATTACCTGCACAATATGACTCCTCCTTTACTTCATCATG 695
Qy  661 ACTTGAAGACTCAGAATATCTTATTGGACAATGAATTTCATGTTAAGATTGCAGATTTTG 720
Db  696 ACTTGAAGACTCAGAATATCTTATTGGACAATGAATTTCATGTTAAGATTGCAGATTTTG 755
Qy  721 GTTTATCAAAGTGGCGCATGATGTCCCTCTCACAGTCACGAAGTAGCAAATCTGCACCAG 780
Db  756 GTTTATCAAAGTGGCGCATGATGTCCCTCTCACAGTCACGAAGTAGCAAATCTGCACCAG 815
Qy  781 AAGGAGGGACAATTATCTATATGCCACCTGAAAACTATGAACCTGGACAAAAATCAAGGG 840
Db  816 AAGGAGGGACAATTATTTATATGCCACCTGAAAACTATGAACCTGGACAAAAATCAAGGG 875
Qy  841 CCAGTATCAAGCACGATATATATAGCTATGCAGTTATCACATGGGAAGTGTTATCCAGAA 900
Db  876 CCAGTATCAAGCACGATATATATAGCTATGCAGTTATCACATGGGAAGTGTTATCCAGAA 935
Qy  901 AACAGCCTTTTGAAGATGTCACCAATCCTTTGCAGATAATGTATAGTGTGTCACAAGGAC 960
Db  936 AACAGCCTTTTGAAGATGTCACCAATCCTTTGCAGATAATGTATAGTGTGTCACAAGGAC 995
Qy  961 ATCGACCTGTTATTAATGAAGAAAGTTTGCCATATGATATACCTCACCGAGCACGTATGA 1020
Db  996 ATCGACCTGTTATTAATGAAGAAAGTTTGCCATATGATATACCTCACCGAGCACGTATGA 1055
Qy 1021 TCTCTCTAATAGAAAGTGGATGGGCACAAAATCCAGATGAAAGACCATCTTTCTTAAAAT 1080
Db 1056 TCTCTCTAATAGAAAGTGGATGGGCACAAAATCCAGATGAAAGACCATCTTTCTTAAAAT 1115
Qy 1081 GTTTAATAGAACTTGAACCAGTTTTGAGAACATTTGAAGAGATAACTTTTCTTGAAGCTG 1140
Db 1116 GTTTAATAGAACTTGAACCAGTTTTGAGAACATTTGAAGAGATAACTTTTCTTGAAGCTG 1175
Qy 1141 TTATTCAGCTAAAGAAAACAAAGTTACAGAGTGTTTCAAGTGCCATTCACCTATGTGACA 1200
Db 1176 TTATTCAGCTAAAGAAAACAAAGTTACAGAGTGTTTCAAGTGCCATTCACCTATGTGACA 1235
Qy 1201 AGAAGAAAATGGAATTATCTCTGAACATACCTGTAAATCATGGTCCACAAGAGGAATCAT 1260
Db 1236 AGAAGAAAATGGAATTATCTCTGAACATACCTGTAAATCATGGTCCACAAGAGGAATCAT 1295
Qy 1261 GTGGATCCTCTCAGCTCCATGAAAATAGTGGTTCTCCTGAAACTTCAAGGTCCCTGCCAG 1320
Db 1296 GTGGATCCTCTCAGCTCCATGAAAATAGTGGTTCTCCTGAAACTTCAAGGTCCCTGCCAG 1355
Qy 1321 CTCCTCAAGACAATGATTTTTTATCTAGAAAAGCTCAAGACTGTTATTTTATGAAGCTGC 1380
Db 1356 CTCCTCAAGACAATGATTTTTTATCTAGAAAAGCTCAAGACTGTTATTTTATGAAGCTGC 1415
```

Wallach

Pseudo w/SID 2



```
Qy       1381 ATCACTGTCCTGGAAATCACAGTTGGGATAGCACCATTTCTGGTTCTCAAAGGGCTGCAT 1440
             ||||||||||||||||||||||||||||||||||||||||||| ||||||||||||||||
Db       1416 ATCACTGTCCTGGAAATCACAGTTGGGATAGCACCATTTCTGGATCTCAAAGGGCTGCAT 1475

Qy       1441 TCTGTGATCACAAGACCACTCCATGCTCTTCAGCAATAATAAATCCACTCTCAACTGCAG 1500
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1476 TCTGTGATCACAAGACCACTCCATGCTCTTCAGCAATAATAAATCCACTCTCAACTGCAG 1535

Qy       1501 GAAACTCAGAACGTCTGCAGCCTGGTATAGCCCAGCAGTGGATCCAGAGCAAAAGGGAAG 1560
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1536 GAAACTCAGAACGTCTGCAGCCTGGTATAGCCCAGCAGTGGATCCAGAGCAAAAGGGAAG 1595

Qy       1561 ACATTGTGAACCAAATGACAGAAGCCTGCCTTAACCAGTCGCTAGATGCCCTTCTGTCCA 1620
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1596 ACATTGTGAACCAAATGACAGAAGCCTGCCTTAACCAGTCGCTAGATGCCCTTCTGTCCA 1655

Qy       1621 GGGACTTGATCATGAAAGAGGACTATGAACTTGTTAGTACCAAGCCTACAAGGACCTCAA 1680
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1656 GGGACTTGATCATGAAAGAGGACTATGAACTTGTTAGTACCAAGCCTACAAGGACCTCAA 1715

Qy       1681 AAGTCAGACAATTACTAGACACTACTGACATCCAAGGAGAAGAATTTGCCAAAGTTATAG 1740
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1716 AAGTCAGACAATTACTAGACACTACTGACATCCAAGGAGAAGAATTTGCCAAAGTTATAG 1775

Qy       1741 TACAAAAATTGAAAGATAACAAACAAATGGGTCTTCAGCCTTACCCGGAAATACTTGTGG 1800
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1776 TACAAAAATTGAAAGATAACAAACAAATGGGTCTTCAGCCTTACCCGGAAATACTTGTGG 1835

Qy       1801 TTTCTAGATCACCATCTTTAAATTTACTTCAAAATAAAAGCATGTAAGTGACTGTTTTTC 1860
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1836 TTTCTAGATCACCATCTTTAAATTTACTTCAAAATAAAAGCATGTAAGTGACTGTTTTTC 1895

Qy       1861 AAGAAGAAATGTGTTTCATAAAAGGATATTTATATCTCTGTTGCTTTGACTTTTTTTATA 1920
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1896 AAGAAGAAATGTGTTTCATAAAAGGATATTTATATCTCTGTTGCTTTGACTTTTTTTATA 1955

Qy       1921 TAAAATCCGTGAGTATTAAAGCTTTATTGAAGGTTCTTTGGGTAAATATTAGTCTCCCTC 1980
             |||||||||||||||||||||||:|:::||:|:|||||:::|||||||||||||||||||
Db       1956 TAAAATCCGTGAGTATTAAAGCTTWAWWRAARGKTCTTTSRKTAAATATTAGTCTCCCTC 2015

Qy       1981 CATGACACTGCAGTATTTTTTTTAATTAATACAAGTAAAAAGTTGAATTTG 2031
             ||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       2016 CATGACACTGCAGTATTTTTTTTAATTAATACAAGTAAAAAGTTGAATTTG 2066
```

RESULT 3
AAZ09246
ID AAZ09246 standard; cDNA; 1931 BP.
XX
AC AAZ09246;
XX
DT 25-OCT-1999 (first entry)
XX
DE Human CARD-3 cDNA.
XX
KW CARD-3; caspase recruitment domain; CARD-4; regulation; detection;
KW caspase activation; detection; screening; therapy; diagnosis; disease;
KW apoptotic cell death; Fas/APO-1 receptor complex; TNF receptor complex;
KW cancer; follicular lymphoma; carcinoma; p53 mutation; viral infection;
KW hormone-dependent tumour; autoimmune disorder; Alzheimer's disease;
KW systemic lupus erythematosis; immune-mediated glomerulonephritis; stroke;
KW Parkinson's disease; amyotrophic lateral sclerosis; retinitis pigmentosa;
KW spinal muscular dystrophy; cerebellar degeneration; anaemia; drug;
KW myelodysplastic syndrome; myocardial infarction; cell proliferation;
KW cell differentiation; cell survival; CARD-4L; CARD-4S; CARD-4Y; CARD-4Z;
KW human; ds.
XX
OS Homo sapiens.
XX
FH Key   Location/Qualifiers
FT CDS   214. .1836
FT   /*tag= a